Anti-Human VHL Monoclonal Antibody (1A521) from ProteoGenix; catalogue ARO-A23289; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The perfect solution for your biotech research needs.
This highly specific and potent antibody targets the human VHL (Von Hippel-Lindau) protein, a key player in cellular pathways involved in tumor growth and angiogenesis. By binding to VHL, this antibody effectively inhibits its function, making it an essential tool for studying VHL-related diseases and potential therapeutic interventions.
The main application of our Anti-Human VHL Monoclonal Antibody is in cancer research. VHL is known to play a crucial role in the development of various cancers, including clear cell renal cell carcinoma and hemangioblastoma. With our antibody, researchers can gain a better understanding of the mechanisms behind these diseases and potentially identify new targets for treatment.
But the potential of this antibody goes beyond cancer research. It has also been shown to be useful in studying other conditions such as polycythemia and pheochromocytoma, where VHL mutations have been implicated. By providing a specific and reliable tool, our antibody allows for more accurate and insightful research in these areas.
In addition to its main applications, our Anti-Human VHL Monoclonal Antibody has also been used in various experimental settings. It has been successfully used in Western blotting, immunoprecipitation, and immunofluorescence assays, demonstrating its versatility and reliability in different techniques.
With its high specificity and potency, our Anti-Human VHL Monoclonal Antibody (1A521) is a valuable addition to any biotech laboratory. Its targeted action and proven effectiveness make it an essential tool for studying VHL-related diseases and potential treatments. Don’t miss the opportunity to enhance your research with this powerful antibody. Order now and take your studies to the next level.
ProteoGenix catalogue number ARO-A23289. For research use only.
Target: von Hippel-Lindau disease tumor suppressor, Protein G7, pVHL, VHL; Clonality: Monoclonal Antibody; Reactivity: Human; Applications: IHC, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
